Results 31 to 40 of about 1,056 (174)

[Translated article] Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis

Actas Dermo-Sifiliográficas, 2022
Interleukin 31 (IL-31) is a neurocytokine that stimulates sensory neurons involved in pruritus. It contributes to skin barrier inflammation, dysfunction, and remodeling.
E. Serra-Baldrich, L.F. Santamaria-Babí, J. Francisco Silvestre   +2 more
doaj   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. [PDF]

J Eur Acad Dermatol Venereol
Itch is the most burdensome symptom in atopic dermatitis (AD) and prurigo nodularis (PN) and is associated with significant psychological distress, sleep deprivation and impaired quality of life.
Ständer S, Elmariah SB, Kwatra SG, Yosipovitch G, Pink AE, Cheong SY, Chen X, Jabbar-Lopez ZK, Ulianov L, Piketty C, Silverberg JI.   +10 more
europepmc   +2 more sources

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus [PDF]

, 2020
© 2019 The Authors Background: Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD) pathogenesis. Objective: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD.
Clucas, Alan, Alexis, Andrew, Lindsey, Lisa, Wollenberg, Andreas, Bouaziz, Jean-David, Ahmad, Faiz, Silverberg, Jonathan I., Bouaziz, Jean David, Pinter, Andreas, Piketty, Christophe, Murrell, Dédée F., Poulin, Yves, Pulka, Grazyna   +12 more
core   +1 more source

Correction: Safety and efficacy of nemolizumab for patients with pruritus: a systematic review and meta-regression analysis of randomized controlled trial [PDF]

Frontiers in Immunology
Junqin Liang, Fengxia Hu, Maoli Dan, Yingbing Sang, Kailibinuer Abulikemu, Qian Wang, Yongzhen Hong, Xiaojing Kang   +7 more
doaj   +2 more sources

Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab [PDF]

Journal of Allergy and Clinical Immunology, 2022
Prurigo nodularis (PN) is a debilitating, difficult-to-treat, intensely pruritic, chronic inflammatory skin disease characterized by hyperkeratotic skin nodules. The pathogenesis of PN is not well understood but is believed to involve cross talk between sensory nerve fibers, immune cells, and the epidermis.
Lam C, Tsoi, Feriel, Hacini-Rachinel, Paul, Fogel, Francois, Rousseau, Xianying, Xing, Matthew T, Patrick, Allison C, Billi, Celine C, Berthier, J Michelle, Kahlenberg, Anne, Lazzari, Henning, Wiegmann, Sonja, Ständer, Christophe, Piketty, Valerie, Julia, Jayendra Kumar, Krishnaswamy, Johann E, Gudjonsson   +15 more
openaire   +2 more sources

Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis

Pharmaceutics, 2023
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not only the immunologic dysfunction and microbiome dysbiosis but also the recovery
Raquel Leao Orfali, Valeria Aoki
doaj   +1 more source

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances

, 2022
BACKGROUNDPatients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo nodularis patients have a high burden of disease, primarily due to the intensity of the itch.
F. Ahmad, G. Yosipovitch, Ständer, S, K. Chaouche, Chaouche, K, C. Piketty, Piketty, C, Ahmad, F, A. Reich, Legat, F J, Lacour, J-P, C. Paul, J.‐P. Lacour, Reich, A, S. Ständer, Yosipovitch, G, Paul, C, F.J. Legat   +17 more
core   +1 more source

Prurigo nodularis en plaque resolved after a loading dose of nemolizumab [PDF]

Baylor University Medical Center Proceedings
Seo Won Cho, Aaron Chen
exaly   +2 more sources

Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues

Frontiers in Medicine, 2021
Pruritus represents one of the most common symptoms in dermatology and general medicine. Chronic pruritus severely impairs the quality of life of affected patients.
Jana Maria Nemmer, Marcus Kuchner, Angeliki Datsi, Angeliki Datsi, Péter Oláh, Péter Oláh, Valérie Julia, Ulrike Raap, Bernhard Homey   +8 more
doaj   +1 more source

Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis

Frontiers in Medicine, 2022
IntroductionPruritus is a major and burdensome symptom in atopic dermatitis (AD). The number of systemic treatments available for AD has increased recently, enabling improved patient relief.ObjectiveTo evaluate the effect of AD treatments on pruritus ...
Youna Rodriguez-Le Roy, Anne-Sophie Ficheux, Laurent Misery, Laurent Misery, Emilie Brenaut, Emilie Brenaut   +5 more
doaj   +1 more source